1. A combination comprising (a) a β2 agonist and (b) an antagonist of muscarinic receptors M3, which is 3 (R) - (2-hydroxy-2,2-dithien-2-yl-acetoxy) -1- (3-phenoxypropyl ) -1-azonium bicyclo [2.2.2] octane in salt form with anion X, which is a pharmaceutically acceptable anion of mono- or polyvalent acid. ! 2. The combination according to claim 1, where the antagonist of the muscarinic receptors M3 (b) is bromide 3 (R) - (2-hydroxy-2,2-dithien-2-yl-acetoxy) -1- (3-phenoxypropyl) -1- azonium bicyclo [2.2.2] octane. ! 3. The combination according to claim 1 or 2, where the β2 agonist is selected from the group consisting of arformoterol, bambuterol, bitolterol, broxaterol, carbuterol, clenbuterol, dopexamine, fenoterol, formoterol, hexoprenaline, ibuterol, isoprenaline, merolol, mabrolol orciprenaline, pirbuterol, carterol, reproterol, rhytodrin, rimoterol, salbutamol, salmeterol, sibenadet, sulfonterol, terbutaline, tulobuterol, GSK-597901, GSK-159797, KUL-1248, TA-2005 and QAB-racate, optionally in the form enantiomers, their diastereomers and their mixtures and neo yazatelno their pharmacologically-compatible acid addition salts. ! 4. The combination of claim 3, wherein the β2 agonist is selected from the group consisting of formoterol, salmeterol and QAB-149, optionally in the form of their racemates, their enantiomers, their diastereomers and their mixtures and optionally their pharmacologically compatible acid addition salts. ! 5. The combination according to claim 4, where the β2 agonist is formoterol fumarate. ! 6. The combination of claim 4, wherein the β2 agonist is salmeterol xinafoate. ! 7. The combination according to claim 3, characterized in that the active ingredients (a) and (b) form part of a single pharmaceutical composition. ! 8.1. Комбинация, содержащая (а) β2-агонист и (b) антагонист мускариновых рецепторов М3, который представляет собой 3(R)-(2-гидрокси-2,2-дитиен-2-илацетокси)-1-(3-феноксипропил)-1-азонийбицикло[2.2.2]октан в форме соли с анион
